drugset
drugset / Trial / NCT00359086

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

NCT00359086 ↗

Phase 2 Completed 74 enrolled Mirati Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.

Timeline

Start
2006-08
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mocetinostat Small molecule — Oral

Indications

lymphoma